Table 3. Sensitivity and specificity estimates for each subgroup.
| Subgroup | No. of studies | Mean SEN (%) | Mean SPE (%) | DOR | AUC (%) |
|---|---|---|---|---|---|
| b value (s/m2) | |||||
| ≥1000 | 5 | 89 (79–95) | 85 (69–93) | 45 (13–160) | 91 (89–94) |
| <1000 | 10 | 88 (79–93) | 76 (64–85) | 22 (12–41) | 90 (87–92) |
| Biomarker | |||||
| ΔADC | 10 | 88 (75–94) | 80 (71–87) | 29 (10–83) | 91 (88–93) |
| Pre-NAC ADC | 6 | 90 (74–96) | 63 (52–73) | 15 (5–41) | 79 (75–82) |
| Post-NAC ADC | 5 | 91 (78–96) | 78 (58–90) | 34 (13–87) | 92 (90–95) |
| Study design | |||||
| Retrospective | 8 | 91 (80–96) | 75 (60–86) | 30 (12–77) | 92 (89–94) |
| Prospective | 4 | 82 (71–84) | 76 (66–84) | 15 (7–34) | 86 (83–89) |
| Magnetic field | |||||
| 1.5T | 9 | 91 (83–95) | 77 (63–87) | 33 (13–80) | 93 (90–95) |
| 3.0T | 6 | 85 (70–91) | 82 (71–89) | 22 (10–47) | 89 (86–91) |
| Model | |||||
| ADC | 13 | 88 (81–93) | 79 (69–87) | 27 (15–50) | 91 (88–93) |
| IVIM | 2 | 86 (64–97) | 76 (63–87) | 14 (3–60) | NA |
Note: Numbers in parentheses are the 95% CIs. NA = not applicable.